Organon (MEX:OGN) ROCE % : 10.55% (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Organon ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Organon's annualized ROCE % for the quarter that ended in Dec. 2024 was 10.55%.

Organon ROCE % Historical Data

The historical data trend for Organon's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organon ROCE % Chart

Organon Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

34.05

23.37

18.22

12.74

14.89

Organon Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															10.42	15.71	16.39	14.24	10.55

Organon ROCE % Calculation

Organon's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	27675.514	/	( ( (204675.482 - 49530.856)	+	(273230.526 - 56685.793) )	/ 2 )
	=	27675.514	/	( (155144.626	+	216544.733)	/ 2 )
	=	27675.514	/	185844.6795
	=	14.89 %

Organon's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	21773.352	/	( ( (251090.706 - 54935.937)	+	(273230.526 - 56685.793) )	/ 2 )
	=	21773.352	/	( ( 196154.769	+	216544.733 )	/ 2 )
	=	21773.352	/	206349.751
	=	10.55 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Organon (MEX:OGN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Organon ROCE % Related Terms

Thank you for viewing the detailed overview of Organon's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Organon Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Organon & Co (MEX:OGN) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

OGN:USA 1OGN:Italy 0A9W:UK 7XP:Germany

Address

30 Hudson Street, Floor 33, Jersey City, NJ, USA, 07302

Website

https://www.organon.com

Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.